Simplify Asset Management Inc. Trims Stock Holdings in Athira Pharma, Inc. $ATHA

Simplify Asset Management Inc. lowered its holdings in Athira Pharma, Inc. (NASDAQ:ATHA) by 90.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 149,279 shares of the company’s stock after selling 1,343,513 shares during the quarter. Simplify Asset Management Inc.’s holdings in Athira Pharma were worth $618,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, BML Capital Management LLC grew its stake in Athira Pharma by 0.9% in the 2nd quarter. BML Capital Management LLC now owns 3,230,667 shares of the company’s stock valued at $976,000 after buying an additional 30,000 shares in the last quarter. Institutional investors and hedge funds own 57.12% of the company’s stock.

Wall Street Analysts Forecast Growth

ATHA has been the topic of several recent research reports. Mizuho set a $4.00 target price on Athira Pharma in a research report on Friday, September 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell” and an average price target of $4.00.

Athira Pharma Price Performance

NASDAQ ATHA opened at $7.50 on Tuesday. The company’s 50 day simple moving average is $4.72 and its two-hundred day simple moving average is $4.12. Athira Pharma, Inc. has a 1 year low of $2.20 and a 1 year high of $8.36. The stock has a market capitalization of $29.55 million, a PE ratio of -0.77 and a beta of 2.95.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($1.51). On average, research analysts anticipate that Athira Pharma, Inc. will post -2.35 EPS for the current year.

Athira Pharma Profile

Athira Pharma, Inc is a clinical?stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease?modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH?1017), a small?molecule positive modulator of the HGF/MET system.